Correction: Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST

Oncotarget. 2021 Nov 23;12(24):2435-2436. doi: 10.18632/oncotarget.28137.

Hsiang-Chih Lu^{1

2}, Vanessa Eulo^{3

2}, Anthony J Apicelli^{4

5}, Melike Pekmezci⁶, Yu Tao⁷, Jingqin Luo⁷, Angela C Hirbe^{8

5}, Sonika Dahiya^{1

5}

¹ Division of Neuropathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
² Co-first authors.
³ Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
⁴ Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
⁵ Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO, USA.
⁶ Department of Pathology, University of California San Francisco School of Medicine, San Francisco, CA, USA.
⁷ Siteman Cancer Center Biostatistics Shared Resource, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
⁸ Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.25195.].